Search

Displaying results 1681 - 1690 of 7687 in total
  1. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  2. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

  3. Drug

    Chromium gluconate

    go.drugbank.com/drugs/DB14528
    Approved

  4. Drug

    Chromium nicotinate

    go.drugbank.com/drugs/DB14529
    Approved

  5. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abemetapir is an inhibitor of these metalloproteinase enzymes, and the first topical pediculicide to take advantage of this novel target.

  6. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due

  7. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  8. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use

  9. Drug

    Lutein

    go.drugbank.com/drugs/DB00137
    ApprovedNutraceutical

    Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids. … In green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very

  10. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.